115 related articles for article (PubMed ID: 4571486)
1. [Are hypoglycemic sulfonamides dangerous?].
Aubertin MJ
Bord Med; 1972 Nov; 5(17):2287-90. PubMed ID: 4571486
[No Abstract] [Full Text] [Related]
2. [Oral therapy in diabetes].
Kirkeby K
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1620-1. PubMed ID: 4588817
[No Abstract] [Full Text] [Related]
3. [Are oral antidiabetics ineffective-or even dangerous? The "University Group Diabetes Program" (UGDP) as basis for a controversial discussion on the therapy of diabetes in the aged].
Teuscher A
Schweiz Med Wochenschr; 1972 Jun; 102(24):848-55. PubMed ID: 5033623
[No Abstract] [Full Text] [Related]
4. The UGDP--tolbutamide and mortality.
Knowles HC
Horm Metab Res; 1974; Suppl 4():186-8. PubMed ID: 4609432
[No Abstract] [Full Text] [Related]
5. [Should the prescription of oral antidiabetic drugs be more limited? Results from controlled clinical trials].
Folling I
Tidsskr Nor Laegeforen; 1973 Aug; 93(23):1604-6. PubMed ID: 4769481
[No Abstract] [Full Text] [Related]
6. The FDA and hypoglycemic drugs.
Davidson JK
JAMA; 1975 May; 232(8):853-5. PubMed ID: 1091764
[No Abstract] [Full Text] [Related]
7. Comments on the UGDP study.
Schöffling K
Horm Metab Res; 1974; Suppl 4():188-91. PubMed ID: 4608018
[No Abstract] [Full Text] [Related]
8. Long-term experience with sulfonylureas and placebo.
Singer DL; Hurwitz D
N Engl J Med; 1967 Aug; 277(9):450-6. PubMed ID: 5340346
[No Abstract] [Full Text] [Related]
9. [Tolbutamide controversy; falling into the pit sobbing].
Touber JL
Ned Tijdschr Geneeskd; 1975 Nov; 119(46):1821-8. PubMed ID: 1107858
[No Abstract] [Full Text] [Related]
10. [University Group Diabetes Program. The UGDP investigation remains clinically unacceptable].
Aarseth S
Tidsskr Nor Laegeforen; 1976 Aug; 96(22):1148. PubMed ID: 951693
[No Abstract] [Full Text] [Related]
11. A note on tolbutamide and diabetes.
Med Lett Drugs Ther; 1970 Jul; 12(14):60. PubMed ID: 4935987
[No Abstract] [Full Text] [Related]
12. Report of the Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents.
JAMA; 1975 Feb; 231(6):583-608. PubMed ID: 1089822
[No Abstract] [Full Text] [Related]
13. Misunderstanding or error? The UGDP report after four years.
Marigo S; Adezati L; Burnetti P; Pozza G; Robba L; Urbinati G
Acta Diabetol Lat; 1974; 11(5):357-422. PubMed ID: 4156992
[No Abstract] [Full Text] [Related]
14. Editorials: Statistical problems in clinical trials: the UGDP study revisited.
Schor SS
Am J Med; 1973 Dec; 55(6):727-32. PubMed ID: 4584989
[No Abstract] [Full Text] [Related]
15. Tolbutamide (Orinase) and diabetes.
Med Lett Drugs Ther; 1970 Nov; 12(24):97-8. PubMed ID: 5514167
[No Abstract] [Full Text] [Related]
16. Controlled clinical trials and the tolbutamide controversy.
Lavietes PH
Conn Med; 1971 Apr; 35(4):271-2. PubMed ID: 4927818
[No Abstract] [Full Text] [Related]
17. [A comparative study of older and newer types of peroral antidiabetics].
Dobesová L; Sieberová R
Vnitr Lek; 1967 Apr; 13(4):344-7. PubMed ID: 4860055
[No Abstract] [Full Text] [Related]
18. Tolbutamide and diabetes.
Can Med Assoc J; 1971 Jun; 104(12):1067. PubMed ID: 5580750
[No Abstract] [Full Text] [Related]
19. The influence of diagnostic criteria on the mortality findings in the University Group Diabetic Programme study of diabetic therapy.
Gray RH
Med J Aust; 1973 Mar; 1(12):594-6. PubMed ID: 4573383
[No Abstract] [Full Text] [Related]
20. The effect of tolbutamide on the diabetic fatty liver.
Beringer A; Hrabal I; Irsigler K; Thaler H
Ger Med Mon; 1968 Dec; 13(12):595-8. PubMed ID: 4898499
[No Abstract] [Full Text] [Related]
[Next] [New Search]
